India’s Supreme Court To Govt: Respond To Charges Of Safety Breech In Gardasil, Cervarix
This article was originally published in PharmAsia News
Executive Summary
In the latest of a series of court interventions, the Supreme Court has asked the regulatory agency to come clear on approvals for Gardasil and Cervarix.
You may also be interested in...
GSK Brings Cervarix To India At Higher Price Than Merck's Gardasil; Will Gynecologists and Pediatricians Help GSK Grab Market Share?
MUMBAI - Overcoming a drawn-out registration and approval process, GlaxoSmithKline has finally launched its much awaited vaccine Cerverix in India. Cerverix is used for the prevention of pre-malignant cervical lesions and cervical cancer related to human pappilomavirus (HPV) types 16 and 18
Merck, Indian Government In Talks For Gardasil Supplies; Aim To Enroll 600 For Mandatory Trials
MUMBAI - Merck has initiated talks with the Indian health ministry to supply Gardasil vaccines for use in government health institutions. Merck has launched the human papillomavirus vaccine Gardasil in India at half its international price and intends to make the drug available to a larger population base through the government's national immunization programs (PharmAsia News, Oct. 14, 2008)
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.